Showing results (1-10 of 438) with videos related to
Sort By:
Pageof 44
Journal of Clinical Epidemiology|September 23, 2024
A meta-epidemiological analysis of post-hoc comparisons and primary endpoint interpretability among randomized noncomparative trials in clinical medicineAlexander D Sherry, Pavlos Msaouel, Ethan B LudmirActa Oncologica (Stockholm, Sweden)|March 24, 2025
Treatment group-specific inferences in Phase III Randomized Oncology TrialsAlexander D Sherry, Adina H Passy, Joseph Abi Jaoude, et al.Cancer Medicine|August 29, 2025
Patient, Physician, and Assessor Blinding in Phase III Randomized Trials in Oncology: A Meta-Epidemiological AnalysisGabrielle Brown, Pavlos Msaouel, Avital M Miller, et al.Journal of the National Cancer Institute|December 27, 2025
Differential censoring in overall survival in phase 3 oncology clinical trialsEric J Hsu, Alexander D Sherry, Timothy A Lin, et al.The Oncologist|June 2, 2024
Lost in the plot: missing visual elements in Kaplan-Meier plots of phase III oncology trialsAlexander D Sherry, Pavlos Msaouel, Ramez Kouzy, et al.Seminars in Radiation Oncology|September 8, 2023
Challenges, Complexities, and Considerations in the Design and Interpretation of Late-Phase Oncology TrialsTimothy A Lin, Alexander D Sherry, Ethan B LudmirJCO Precision Oncology|September 30, 2024
Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in OncologyAlexander D Sherry, Pavlos Msaouel, Gabrielle S Kupferman, et al.JCO Oncology Practice|January 8, 2025
Incomplete Toxicity Reporting and Use of Toxicity-Minimizing Language in Phase III Oncology TrialsAvital M Miller, Adina H Passy, Alexander D Sherry, et al.Cancer|February 7, 2026
Control arm overperformance in phase 3 oncology clinical trialsAnsel P Nalin, Pavlos Msaouel, Adam J Grippin, et al.JAMA Network Open|March 28, 2024
Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020Alexander D Sherry, Andrew W Hahn, Zachary R McCaw, et al.Pageof 44